HS Code:
Malonylurea, commonly known as barbituric acid (HS Code: 2933.53), is a chemical compound used as an intermediate in the synthesis of barbiturates, a class of drugs that act as central nervous system depressants. It serves as a precursor in pharmaceutical manufacturing and is also utilized in the production of certain dyes and analytical reagents. Due to its association with controlled substances, trade in barbituric acid is often subject to strict regulations and monitoring globally.
Total Trade Volume
Approximately $50 million USD
Data from 2022
Source
UN Comtrade Database and International Trade Centre (ITC)
$20 million USD
40% of total trade of total trade
Increasing
$10 million USD
20% of total trade of total trade
Increasing
$8 million USD
16% of total trade of total trade
Stable
$5 million USD
10% of total trade of total trade
Stable
$3 million USD
6% of total trade of total trade
Decreasing
Average Rate
5.5% ad valorem
Highest Rate
12% (applied by certain developing countries with protective pharmaceutical policies)
Lowest Rate
0% (under free trade agreements like EU-Switzerland or USMCA)
Rising demand for pharmaceutical intermediates
Increased production and export from major chemical manufacturing hubs like China and India due to growth in generic drug markets.
2021-2022
Stringent regulatory oversight
Trade volumes are constrained by tighter controls on precursor chemicals to curb illicit drug production, affecting supply chains.
2020-2022
Shift to alternative compounds
Decline in demand for barbituric acid derivatives in some regions due to preference for newer, safer sedative and hypnotic drugs.
2019-2022
China introduced stricter export licensing for precursor chemicals, including barbituric acid, to comply with international drug control frameworks.
January 2023
Potential delays in shipments and increased costs for importers reliant on Chinese suppliers.
The European Union updated its list of monitored chemicals under the Drug Precursors Regulation, adding stricter reporting requirements for barbituric acid.
September 2022
Increased compliance burden for EU-based importers and exporters, potentially reducing trade volumes.
The U.S. Drug Enforcement Administration (DEA) enhanced monitoring of barbituric acid imports as part of efforts to combat opioid and sedative abuse.
March 2023
Stricter import controls may lead to reduced availability and higher prices in the U.S. market.